AstraZeneca to buy US firm ZS Pharma for $2.7bn

It will give UK-based AstraZeneca access to a drug that could potentially treat life-threatening condition, hyperkalaemia.
The drug, ZS-9, is currently under regulatory review by the US Food and Drug Administration.